-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Oragenics, Inc. Files 10K and Provides Company Update
Oragenics, Inc. Files 10K and Provides Company Update
Oragenics, Inc. Files 10K and Provides Company Update
SARASOTA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (the "Company") (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has executed on its strategy to diversify its product development portfolio and makes progress in transforming the Company to create long term value. Some key items that have helped to improve the Company moving forward are:
- The Company acquired a platform technology intended to treat multiple neurological disorders. The first target indication is for concussion and the technology has successfully completed a Phase I trial.
- Raised approximately $ 2.1 million in a public offering and $890,000 in a private transaction.
- Hired a Chief Medical Officer: Dr James Kelly MD, is a thought leader in brain injury including concussion.
- Added two new Board members: John Gandolfo and Bruce Cassidy.
- Created a subsidiary in Australia to take advantage of R&D rebates offered by the Australian government.
- Contracted with a leading Contract Research Organization to oversee our Phase II clinical trial.
- Manufacturing drug in preparation for our Phase II trial.
We are excited about the progress the Company has made in the past several months. We are creating a team with the experience and drive to further our neurological drug candidates through clinical trials during 2024," commented Michael Redmond, President of Oragenics.
As previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 29, 2024 with the Securities and Exchange Commission, the audited consolidated financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. See further discussion in footnote 1 of the Company's consolidated financial statements included in the Company's Annual Report on Form 10-K.
About Oragenics
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328369604/en/
Oragenics, Inc.
Janet Huffman, Chief Financial Officer
813-286-7900
jhuffman@oragenics.com
LHA Investor Relations
Tirth T. Patel
212-201-6614
tpatel@lhai.com
Source: Oragenics, Inc.
Released April 1, 2024
Oragenics, Inc. Files 10K and Provides Company Update
Oragenics, Inc. 提交了 10K 文件并提供公司最新情况
SARASOTA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (the "Company") (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has executed on its strategy to diversify its product development portfolio and makes progress in transforming the Company to create long term value. Some key items that have helped to improve the Company moving forward are:
佛罗里达州萨拉索塔--(美国商业资讯)--专注于开发用于治疗神经系统疾病的独特鼻内药物的公司Oragenics, Inc.(“公司”)(纽约证券交易所美国股票代码:OGEN)今天宣布,已于2024年3月29日提交年度报告。该公司高兴地报告,它已经执行了多元化产品开发组合的战略,并在公司转型以创造长期价值方面取得了进展。一些有助于改善公司前进的关键项目是:
- The Company acquired a platform technology intended to treat multiple neurological disorders. The first target indication is for concussion and the technology has successfully completed a Phase I trial.
- Raised approximately $ 2.1 million in a public offering and $890,000 in a private transaction.
- Hired a Chief Medical Officer: Dr James Kelly MD, is a thought leader in brain injury including concussion.
- Added two new Board members: John Gandolfo and Bruce Cassidy.
- Created a subsidiary in Australia to take advantage of R&D rebates offered by the Australian government.
- Contracted with a leading Contract Research Organization to oversee our Phase II clinical trial.
- Manufacturing drug in preparation for our Phase II trial.
- 该公司收购了一项旨在治疗多种神经系统疾病的平台技术。第一个目标适应症是脑震荡,该技术已成功完成I期试验。
- 通过公开募股筹集了约210万美元,通过私人交易筹集了890,000美元。
- 聘请首席医疗官:医学博士詹姆斯·凯利博士是包括脑震荡在内的脑损伤领域的思想领袖。
- 增加了两名新的董事会成员:约翰·甘道夫和布鲁斯·卡西迪。
- 在澳大利亚成立了一家子公司,以利用澳大利亚政府提供的研发折扣。
- 与一家领先的合同研究组织签约,监督我们的二期临床试验。
- 制造药物,为我们的二期试验做准备。
We are excited about the progress the Company has made in the past several months. We are creating a team with the experience and drive to further our neurological drug candidates through clinical trials during 2024," commented Michael Redmond, President of Oragenics.
我们对公司在过去几个月中取得的进展感到兴奋。Oragenics总裁迈克尔·雷德蒙德评论说,我们正在组建一支具有丰富经验和动力的团队,通过临床试验进一步发展我们的神经系统候选药物。
As previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 29, 2024 with the Securities and Exchange Commission, the audited consolidated financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. See further discussion in footnote 1 of the Company's consolidated financial statements included in the Company's Annual Report on Form 10-K.
正如先前在2024年3月29日向美国证券交易委员会提交的截至2023年12月31日的10-K表年度报告中披露的那样,经审计的合并财务报表包含其独立注册会计师事务所的无保留审计意见,其中包括与公司继续经营能力有关的解释性段落。请参阅公司10-K表年度报告中公司合并财务报表脚注1中的进一步讨论。
About Oragenics
关于 Oragenics
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.
Oragenics是一家处于开发阶段的生物技术公司,专注于神经病学和对抗传染病药物的鼻腔输送,包括用于治疗轻度创伤性脑损伤(mtBI)(也称为脑震荡)和治疗C型尼曼·皮克病(NPC)的候选药物,以及专有的粉末配方和鼻内输送设备。欲了解更多信息,请访问 www.oragenics.com。
Forward-Looking Statements
前瞻性陈述
This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
本通信包含《1995年美国私人证券诉讼改革法》安全港条款所指的 “前瞻性陈述”。这些前瞻性陈述基于管理层的信念、假设和当前可用的信息。“相信”、“期望”、“预测”、“打算”、“估计”、“项目” 等词以及不只与历史问题相关的类似表述可识别前瞻性陈述。投资者在依赖前瞻性陈述时应谨慎行事,因为前瞻性陈述受到各种风险、不确定性和其他因素的影响,这些因素可能导致实际业绩与任何此类前瞻性陈述中表达的业绩存在重大差异。这些因素包括但不限于我们在10-K表格和向美国证券交易委员会提交的其他文件中描述的因素。本新闻稿中列出的所有信息均截至本新闻稿发布之日。在评估本新闻稿中包含的前瞻性陈述时,您应考虑这些因素,不要过分依赖此类陈述。除非法律另有规定,否则如果情况发生变化,我们不承担任何义务公开对任何前瞻性陈述进行修订或更新,无论是由于新信息、未来发展还是其他原因。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328369604/en/
在 businesswire.com 上查看源版本: https://www.businesswire.com/news/home/20240328369604/en/
Oragenics, Inc.
Janet Huffman, Chief Financial Officer
813-286-7900
jhuffman@oragenics.com
Oragenics, Inc.
珍妮特·霍夫曼,首席财务官
813-286-7900
jhuffman@oragenics.com
LHA Investor Relations
Tirth T. Patel
212-201-6614
tpatel@lhai.com
LHA 投资者关系
Tirth T. Patel
212-201-6614
tpatel@lhai.com
Source: Oragenics, Inc.
资料来源:Oragenics, Inc.
Released April 1, 2024
2024 年 4 月 1 日发布
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧